



Tetrahedron Letters 44 (2003) 9331–9335

TETRAHEDRON LETTERS

Synthesis of new peptidic glycoclusters derived from β -alanine

Koji Sato, Noriyasu Hada and Tadahiro Takeda*

Kyoritsu College of Pharmacy, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan Received 9 July 2003; revised 10 October 2003; accepted 10 October 2003

Abstract—The synthesis of an asymmetric glycocluster 1 has been achieved by coupling of a sugar unit with the β -alanine polypeptide, the principal chain, and combining a carbohydrate chain with the side chain causing it to branch from the N terminal. The synthesis of this side chain multivalent ligands is based on the scaffolding of some ω -amino acid (glycine, β -alanine, and GABA) derivatives. This method facilitated the synthesis of the cluster, of which the length of each unit differs. © 2003 Elsevier Ltd. All rights reserved.

The carbohydrate portions of glycoconjugates in the cell surface participates at a macromolecular level in many biological recognition processes, such as those involving immune defense response, viral replication, parasite infection, cell-cell adhesion and inflammation.¹ The research of many glycobiologists is, therefore, often concentrated on detailed investigation of carbohydrateprotein interactions which might eventually lead to the development of carbohydrate-based drugs and prove to be an important tool for investigation of their function. With the carbohydrate chain localized intracellularly to form a microdomain, reciprocal interactions demonstrate increased binding affinity with certain proteins when compared with the individual monomeric unit.² By using the cluster carbohydrate chain (glycocluster) in a synthetic carbohydrate, it is reported that the bioactivation is strengthened. Glycoclusers have proved to be advantageous in many instances, as the multipresentation of a specific sugar epitope in one molecule can result in remarkably increased adhesion. It is expected that multivalent carbohydrates would bind to the cell surface adhesion molecule more tightly than monovalent ones. The past method for the synthesis of glycoclusters³ has an advantage over ours in view of the repeated simultaneous equivalent reactions needed in ours for the polyvalence functional group to amplify the carbohydrate chain exponentially. However, in the previous method only the symmetrical structure could be taken.

0040-4039/\$ - see front matter @ 2003 Elsevier Ltd. All rights reserved. doi:10.1016/j.tetlet.2003.10.073

This paper will focus on a newly designed glycocluster derived from β -alanine. Glycoclusters of this type are now more than 10 years old, without considering the pioneering work of Y. C. Lee et al.⁴ who made analogous structures based on aspartic acid and that of R. Roy et al.⁵ on lysine and glycines. The new glyco-cluster which we synthesized involves making the β -ala-



1

Scheme 1.

Keywords: glycocluster; β -peptide; D-galactose; unit synthesis; carbohydrate-protein interaction.

^{*} Corresponding author. Tel.: +81(3)54002696; fax: +81(3)54002556; e-mail: takeda-td@kyoritsu-ph.ac.jp

nine polypeptide the principal chain, and combining a carbohydrate chain with the side chain causing it to branch from the N terminal. Unlike the cluster using the usual amino acid, the problem of racemization in the amide condensation was avoided by using the N terminal β -alanine. Furthermore, by using some ω -amino acid (glycine, β -alanine, and GABA) it facilitated the synthesis of the cluster, of which the length of each unit differs. We describe the synthesis of new asymmetric peptide glycoclusters of which the length partially differs.

In this paper we report the synthesis of the glycocluster 1 of dancyl-labelled β -alanine trees, depicted in Scheme 1. The dancyl probe will allow flow cytometric analysis of the interaction and the uptake of the constructions by human dendritic cells.

First, the synthesis of the four desired compounds 9, 16, 17, and 18, which were selected as the glycocluster units, is shown in Scheme 2. Preparation of the *N*-carboxymethyl β -alanine derivative 7 was prepared from β -alanine by the following six-step procedure. β -Alanine was protected with 2,2,2-trichloroethanol and fur-

amino was protected ther, the group with *p*-nitrobenzenesulfonyl (*p*NBS) chloride to give 3. *N*-Carboxymethylation of 3 was carried out by the Mitsunobu protocol⁶ with benzyl glycolate to give compound 4. Removal of the pNBS group by PhSH and K_2CO_3 in DMF at 25°C⁷ and subsequent *t*-butoxycarbonylation by $(Boc)_2O$ gave compound 6. This compound 6 has two carboxylic acid derivatives, and it is a chemical compound with the features which can expand the sugar units by being, respectively, independent. Condensation of 7 with sugar unit 8, which is a simple galactose derivative, in the presence of typical peptide coupling conditions [DEPC (diethyl cyanophosphonate) and Et₃N] was carried out for 16 h at 25°C to give the coupled compound 9.8 On the other hand, coupling of 7 with each ω -amino acid (glycine, β -alanine, and GABA) benzyl ester under DEPC for 16 h at 25°C gave dipeptide derivative 10, 11 and 12. Subsequent removal of the benzyl ester of compound 10, 11 and 12 by catalytic hydrogenolysis over 10% Pd-C afforded compounds 13, 14 and 15. Furthermore, coupling of 8 with 13, 14 and 15 in the presence of DEPC as described for 9 gave the different length of each side chain of derivatives 16, 17 and 18.9



Scheme 2. *Reagents and conditions*: (a) *p*-Nitrobenzenesulfonyl chloride, Et₃N, CH₂Cl₂, 86%; (b) benzyl glycolate, DEAD, PPh₃, CH₂Cl₂, 90%; (c) PhSH, K₂CO₃, DMF, 81%; (d) (Boc)₂O, Et₃N, CH₂Cl₂, 94%; (e) Pd-C, H₂, THF, **7**: 84%, **13**: 80%, **14**: 99%, **15**: 82%; (f) sugar unit **8**, DEPC, Et₃N, DMF, **9**: 78%, **16**: 80%, **17**: 76%, **18**: 80%; (g) ω-amino acid benzylester, DEPC, Et₃N, DMF, **10**: 84%, **11**: 82%, **12**: 92%.



Scheme 3. *Reagents and conditions*: (a) Zn–AcOH, 19: 75%, 22: 75%, 23: 89%, 26: 76%; (b) 50% TFA, 20: 79%, 24: 76%, 28: 82%; (c) DEPC, Et₃N, DMF, 21: 98%, 25: 94%; (d) sugar unit 8, DEPC, Et₃N, DMF, 88%.

Next, compounds 22 and 28 were selected as the Nterminal block and C-terminal block, respectively, and are shown in Scheme 3. Glycocluster unit 19 derived from 9 by reductive removal of the trichloroechyl group using Zn-AcOH was treated with another glycocluster unit 20 derived from 16 by removal of the Boc group using 50% TFA under coupling conditions as described for 9 to afford cluster block 21. Then, removal of the trichloroechyl group from 21 by ZnAcOH gave the N-terminal block compound 22. On the other hand, compound 25 was obtained by coupling of 23 from 17 with 24 from 18 in the presence of DEPC as described for 21, and subsequent removal of the trichloroechyl group from 25 gave compound 26. Furthermore, coupling of 26 with sugar unit 8 gave 27 and removal of the Boc group using 50% TFA gave the target C-terminal block compound 28.



Scheme 4. Reagents and conditions: (a) DEPC, Et_3N , DMF, 80%; (b) 50% TFA, 83%; (c) dansyl glycine, DEPC, Et_3N , DMF, 77%; (d) NaOMe, MeOH, 1,4-dioxane, 94%.

Finally, coupling of 22 with 28 in the presence of DEPC as described for 21 gave the pentamer derivative 29. The Boc group of 29 was removed under acidic conditions with 50% TFA giving a free secondary amino group, which was subsequently treated with dancyl glycine under DEPC giving 31. Then, complete de-*O*-benzoylation of 31 afforded the target compound 1 with free hydroxyl groups on all the asymmetric glycoclusters.¹⁰ (Scheme 4) At this time, each step gave, respectively, a high yield and there were no by-products generated in the peptide condensation.

In conclusion, efficient and widely applicable synthetic strategies in glycoconjugate chemistry have given access to a new glycocluster. The glycocluster was synthesized this time in order to optionally change the distance from the core to the carbohydrate chain and the distance between carbohydrate chains, thus becoming the cluster with the optimum structure which fits the structure of the carbohydrate chain recognition domain, and higher biological activities are expected.

Typical procedure: To a solution of compound **13** (81.2 mg, 0.19 mmol) and compound **8** (143.0 mg, 0.22 mmol) in DMF (2 mL) were added DEPC (34 μ L, 0.22 mmol) and triethylamine (52 μ L, 0.37 mmol). The reaction mixture was stirred for 16 h at 25°C. After completion of the reaction, the mixture was extracted with ethyl acetate, washed with water, dried (Mg₂SO₄), and concentrated. The product was purified by silicagel column chromatography (benzene: acetone = 5:1) as elute to give compound **16** (156.8 mg, 79.6%).

Acknowledgements

This work was supported by a Grant-in-Aid for Scien-

tific Research (No. 14771250) from the Ministry of Education, Science, Sports and Culture of Japan. We gratefully acknowledge financial support in the form of a Sasagawa Scientific Research Grant and the Tokyo Biochemical Research Foundation Grant. The authors are grateful to Ms. J. Hada for providing NMR and MS data.

References

- (a) Essential of glycobiology; Varki, A., Cummings, R., Esko, J., Freeze, H., Haet, G., Marth, J., Eds., Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 1991; (b) Molecular Glycobiology; Fukuda, M., Hindsgaul, O., Eds.; Oxford University Press: New York, 1994.
- 2. (a) Lee, Y. C.; Lee, R. T. Acc. Chem. Res. 1995, 28, 321;
 (b) Lasky, L. A. Annu. Rev. Biochem. 1995, 64, 113.
- (a) Roy, R. J. Carbohydr. Chem. 2002, 21, 769; (b) Langer, P.; Ince, S. J.; Ley, S. V. J. Chem. Soc., Perkin Trans. 1 1998, 3913; (c) Ashton, P. R.; Boyd, S. E.; Brown, C. L.; Jayaraman, N.; Stoddart, J. F. Angew. Chem., Int. Ed. Engl. 1997, 36, 732; (d) Lindhorst, T. K.; Ludewig, M.; Thiem, J. J. Charbohydr. Chem. 1998, 17, 1131.
- (a) Lee, Y. C.; Lee, R. T. *The glycoconjugates*; Horowits, M. I., Ed.; Academic Press: New York, NY, 1982; Vol. IV, p. 57; (b) Lee, R. T.; Lee, Y. C. *Biochemistry* 1984, 23, 4255.
- (a) Khan, S. H.; O'Neill, R, A. Modern Methods in Carbohydrate Synthesis; Harwood Academic Publishers; 1996, p. 378; (b) Roy, R. Curr. Opin. Struct. Biol. 1996, 6, 692.
- 6. Mitsunobu, O. Synthesis 1981, 1.
- Fukuyama, T.; Jow, C.-K.; Cheung, M. *Tetrahedron Lett.* 1995, 36, 6373.

- 8. Physical data for **9**: $[\alpha]_{23}^{23} = +59.0^{\circ}$ (*c*=1.9, CHCl₃) ¹H NMR (500 MHz, CDCl₃): δ 8.10–7.23 (20H, m, Ar-H), 6.25 (1H, s, NH), 6.00 (1H, d, H-4), 5.77 (1H, dd, *J*=10.4 Hz, H-2), 5.63 (1H, dd, *J*=3.1 Hz, H-3), 4.87 (1H, d, *J*=7.9 Hz, H-1), 4.72 (2H, s, CH₂CCl₃), 4.67 (1H, dd, H-6a), 4.45 (1H, dd, H-6b), 4.36 (1H, m, H-5), 3.98 and 3.76 (2H, m, OCH₂ of sugar unit), 3.65 (2H, s, NCH₂CO), 3.55–3.49 (4H, m, NCH₂ of sugar unit, NCH₂ of β-alanine), 2.72 (2H, t, *J*=6.7 Hz, COCH₂ of β-alanine), 1.43 (9H, s, *t*-Bu). ¹³C NMR (125 MHz, CDCl₃): δ 169.3, 166.0, 165.5, 165.3, 133.7, 133.5, 133.4, 133.3, 130.0, 129.7, 129.3, 129.2, 129.0, 128.7, 128.6, 128.5, 128.3, 101.7, 94.8, 80.9, 74.1, 71.6, 71.5, 69.8, 68.9, 68.1, 62.1, 51.7, 44.9, 39.2, 33.0, 28.3. MALDI-TOFMS: calcd for C₄₈H₄₉Cl₃N₂O₁₅: 998, found 1021[M+Na]⁺.
- 9. Physical data for **16** $[\alpha]_{D}^{23} = +57.5^{\circ}$ (c=1.9, CHCl₃) ¹H NMR (500 MHz, CDCl₃): δ 8.10–7.23 (20H, m, Ar-H), 6.42 (1H, s, NH), 6.01 (1H, s, NH), 6.00 (1H, d, H-4), 5.75 (1H, dd, $J_{2,3} = 10.4$ Hz, H-2), 5.64 (1H, dd, $J_{3,4} = 3.1$ Hz, H-3), 4.84 (1H, d, $J_{1,2} = 7.9$ Hz, H-1), 4.71 (2H, s, CH₂CCl₃), 4.69 (1H, dd, H-6a), 4.44 (1H, dd, H-6b), 4.36 (1H, t, H-5), 3.99, 3.75 (2H, m, CH₂O of sugar unit), 3.89 (2H, s, NCH₂CO), 3.68–3.40 (6H, m, NHCH₂CO, NCH₂C, CONHCH₂), 2.79 (2H, t, COCH₂C), 1.46 (9H, s, *t*-Bu). ¹³C NMR (125 MHz, CDCl₃): δ 169.5, 166.1, 165.5, 165.5, 133.7, 133.4, 130.0, 129.7, 129.7, 129.3, 129.0, 128.7, 128.5, 128.3, 101.6, 94.7, 81.3, 74.1, 71.6, 71.4, 70.0, 68.6, 68.1, 52.3, 45.0, 42.5, 39.2, 33.4, 28.3. HR-FABMS: calcd for C₅₀H₅₂Cl₃N₃O₁₆: 1055.2413, found 1056.2516[M+H]⁺.

Physical data **17** $[\alpha]_D^{23} = +53.0^{\circ}$ (c = 1.8, CHCl₃) ¹H NMR (500 MHz, CDCl₃): δ 8.10–7.23 (20H, m, Ar-H), 6.79 (1H, s, NH), 6.00 (1H, d, H-4), 5.96 (1H, s, NH), 5.76

(1H, dd, $J_{2,3}$ =10.4 Hz, H-2), 5.65 (1H, dd, $J_{3,4}$ =3.6 Hz, H-2), 4.84 (1H, d, $J_{1,2}=7.9$ Hz, H-1), 4.74 (2H, s, CH₂CCl₃), 4.68 (1H, dd, H-6a), 4.44 (1H, dd, H-6b), 4.36 (1H, t, H-5), 4.01, 3.70 (2H, m, OCH₂ of sugar unit), 3.85 (2H, s, COCH₂N), 3.60 (2H, t, NCH₂ of β-alanine), 3.57-3.34 (4H, m, NCH₂ of sugar unit, NCH₂ of β-alanine), 2.78 (2H, t, CH₂CO), 2.11 and 1.99 (2H, m, CH₂CO), 1.44 (9H, s, t-Bu). ¹³C-NMR (125 MHz, CDCl₃): *δ* 171.4, 169.1, 166.0, 165.5, 165.4, 133.4, 130.0, 129.7, 129.7, 129.3, 128.9, 128.7, 128.5, 128.3, 101.6, 94.8, 81.0, 74.0, 71.6, 71.3, 69.9, 68.9, 68.0, 62.0, 52.0, 44.8, 39.0, 35.2, 34.7, 33.2, 28.2. HR-FABMS: calcd for C₅₁H₅₄Cl₃N₃O₁₆: 1069.2570, found 1070.2609[M+H]⁺. Physical data **18** $[\alpha]_{D}^{23} = +53.5^{\circ} (c = 1.8, \text{ CHCl}_{3})$ ¹H NMR (500 MHz, CDCl₃): & 8.10-7.23 (20H, m, Ar-H), 6.69 (1H, s, NH), 6.10 (1H, s, NH), 6.01 (1H, d, H-4), 5.77 (1H, dd, H-2), 5.65 (1H, dd, H-3), 4.86 (1H, d, H-1), 4.73 (2H, s, CH₂CCl₃), 4.69 (1H, dd, H-6a), 4.44 (1H, m, H-6b), 4.37 (1H, t, H-5), 4.01 and 3.72 (2H, OCH2 of sugar unit), 3.85 (2H, s, COCH₂N), 3.62 (2H, t, NCH₂ of β-alanine), 3.56-3.34 (2H, m, NCH₂ of sugar unit), 3.18 (2H, m, NCH₂ of GABA), 2.77 (2H, t, CH₂CO of β-alanine), 2.01-1.85 (2H, m, CH₂CO of GABA), 1.67 (2H, m, CCH₂C), 1.44 (9H, s, t-Bu). ¹³C NMR (125 MHz, CDCl₃): δ 172.6, 169.5, 166.0, 165.5, 165.4, 133.64, 133.61, 133.3, 120.0, 129.7, 129.3, 129.04, 128.95, 128.64, 128.61, 128.5, 128.3, 101.6, 94.7, 81.0, 74.1, 71.5, 71.4, 69.9, 69.0, 68.1, 62.0, 52.1, 44.9, 39.1, 39.0, 33.3, 28.3, 24.8. HR-FABMS: calcd for C₅₂H₅₆Cl₃N₃O₁₆: 1083.2726, found 1084.2780[M+H]+.

 MALDI-TOFMS of final compound 1: calcd for C₈₃H₁₃₄N₁₄O₄₄: 2063, found: 2086 [M+Na]⁺.